神黄颗粒治疗重型COVID-19:开放标签随机对照试验方案
本研究为多中心、开放标签随机对照试验,计划纳入160例重型COVID-19患者,按1:1随机分为神黄颗粒组和对照组,均接受标准治疗,神黄颗粒每日两次、疗程14天。主要结局为14天临床结局,旨在评估神黄颗粒的疗效与安全性,为重型COVID-19治疗提供循证依据。
要点
- 神黄颗粒每日两次联合标准治疗,疗程14天,主要观察14天临床结局。
- 试验为多中心、开放标签、1:1随机对照设计,计划纳入160例重型COVID-19患者。
- 安全性通过全程不良事件监测评估,结果可为中医药治疗重型COVID-19提供证据。
核心结论
- 该试验旨在评估神黄颗粒治疗重型COVID-19的疗效与安全性,结果可能为临床提供循证推荐并丰富中医药治疗传染病的理论与实践。
研究设计与样本
- 多中心、开放标签、随机对照试验,计划纳入160例重型COVID-19患者,按1:1随机分为治疗组和对照组。
- 所有参与者同时接受标准治疗,治疗组接受神黄颗粒每日两次、疗程14天。
- 主要结局为14天临床结局,临床指标在基线及治疗开始后第3、5、7、14天评估,全程监测不良事件。
关键数值与推荐
- 主要结局为14天临床结局;神黄颗粒每日两次,疗程14天;计划样本量160例;随机比例1:1。
临床怎么用
- 若试验证明有效且安全,神黄颗粒联合标准治疗或可作为重型COVID-19的循证治疗选择,供临床医生参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, coronavirus disease 2019 (COVID-19) is continuously and rapidly circulating, causing heavy damage on public health. No effective antiviral treatment has been proved thus far. Traditional Chinese medicine (TCM) has been widely applied in the treatment of a variety of infection diseases in China, hoping to produce clinical effects and reduce the use of antibiotics and glucocorticoid. The aim of this study is to evaluate the efficacy and safety of Shenhuang granule in treatment of severe COVID-19. METHODS/DESIGN: This multicenter, open-label randomized controlled trial is conducted in 160 participants with severe COVID-19. The participants will be randomly (1:1) divided into treatment group or control group. All participants are given standard therapy at the same time. The experiment will receive Shenhuang granule treatment twice a day for 14 days. The clinical indicators of patients will be assessed at baseline and at 3, 5, 7, and 14 days after treatment initiation. The primary outcome is 14-day clinical outcome. Adverse events will be monitored throughout the trial. DISCUSSION: This will be the first randomized controlled trial, which evaluate the effect of Shenhuang granule in patients with severe COVID-19 in China. The results of this trial may not only provide evidence-based recommendations to clinicians to treat severe COVID-19, but also enrich the theory and practice of TCM in treating infectious diseases. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000029777. Registered on 13 February 2020.
引用
- Fang B, Zhang W, Wu X, et al. Shenhuang granule in the treatment of severe coronavirus disease 2019 (COVID-19): study protocol for an open-label randomized controlled clinical trial. Trials. 2020. PMID: 32580752. doi:10.1186/s13063-020-04498-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。